Laser therapy could ease menopause symptoms without hormones
NCT ID NCT04042766
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a laser treatment for women with Genitourinary Syndrome of Menopause (GSM), which causes vaginal dryness, itching, and pain. About 60 postmenopausal women will receive the Er:YAG laser procedure. The goal is to see if it reduces their most bothersome symptom, offering an alternative to creams or hormones.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Er:YAG laser procedure
- What this could lead to
- If it works, this could offer a non-hormonal, long-lasting option to ease vaginal discomfort and urinary symptoms after menopause.
- What could go wrong
- This is a small, early-stage trial with only 60 participants. The laser may not work better than existing treatments, and long-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2019
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 70 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Females aged 45-70 years; 2. 2 or more years since last natural menstrual period, or surgical menopause (bilateral oophorectomy); 3. at least 1 vaginal symptom reported from the following list, experienced for the past 30 days which is moderate or severe at least once a week: dryness \| itching \| irritation \| soreness/pain \| dyspareunia; 4. no concurrent or new planned treatment for GSM during the treatment period and the 3 months following it; 5. vaginal anatomy allows for laser therapy; 6) willing and able to comply with the study protocol. Exclusion Criteria: 1. Patient is pregnant/lactating 2. unexplained abnormal genital bleeding 3. current acute vaginal/ bladder infection 4. antibiotic use the past 30 days; 5. women under age 55 with endometrial ablation/ hysterectomy/ at least one ovary; 6. concurrent use of any other new GSM treatment 7. pelvic surgery \<3 months 8. current treatment for chronic pelvic pain
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Menopausal urethral atrophy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sunnybrook Health Sciences Centre, University of Toronto
Toronto, Ontario, M4N 3M5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.